Bangalore-based Sami Labs has received US patents on three
new active ingredients- Tetrahydrocurcuminoids (THC), Coleus
Oil and ZeaLutien. THC is a decolorized extract from turmeric,
applied in dermatology, coleus oil is an extract from coleus,
a waste product and finds application as an anti-infective
agent and Zealutien is extracted from Chilly and Marigold,
finding application in geriatric Ophthalmology field.
three active ingredients in the nutraceuticals and cosmeceuticals
formulations have a combined estimated market size of Rs.
currently manufactures about 2.5 tonnes of THC, 1.5 tonne
of ZeaLutien and none of Coleus oil. “ Targeting specifically
at the US market, we would be significantly increasing our
capacities,” said Dr. Muhammed Majeed, Chairman and
Managing Director, Sami Labs.
current international price per kg is $ 300 for THC, $80
for Coleus oil and $ 250 for ZeaLutien. “ After getting
patent on their applications, the prices of these products
are bound to increase,” he added.
company is also awaiting patent approvals from India, Europe
and Japan for the above-mentioned three ingredients.
three patents take the total number of approved patents
at nine for the company. 15 more patents are pending with
the US FDA.
Labs achieved a turnover of Rs. 71 crore for the year ended
March 2003. “ In the next three years, we are hoping
to grow by 25-30 per cent,” he said.
Majeed was specifically unhappy over a lack of stricter
IPR laws in the country. “The Indian business environment
is challenging for us, especially in the absence of strong
protection laws against infringement of intellectual property.
We believe that patents and exclusive marketing rights strengthen
the product life cycle and provide patient population an
access to better healthcare solutions. The concern here
is how effectively the government will safeguard the interest
of the product/process patent holder when using flexibilities
such as those cited for epidemics by developing countries.
This arrangement will be detrimental to creating a level
playing field for Indian and multinational producers of
therapeutic solutions.” He said.
has so far invested close to Rs. 60 crore in four production
units at Bangalore, Singasandra, Kunigal and Mysore. Sami
Labs’ interest in India is evident from its recent
infusion of Rs. 60 crore in its R&D facility located
at Bangalore. Over the years, Sami has built up R&D
team of over 100 scientists, including 20 doctorates in
Additionally, the company is driving biotech research in
probiotics and is expected to roll out products by the end
of 2004. The company is targeting Rs. 100 crore turnover
for its formulations business in India by the close 2006.
The company is also exploring business opportunities in